Calquence PhIII ASCEND trial met primary endpoint
7 May 2019 07:00 BST Calquence Phase III ASCEND trial met primary endpoint at interim analysisin relapsed or refractory chronic lymphocytic leukaemia and will stop early Calquence significantly increased the timepatients live without disease progression AstraZeneca today announced positive results from the Phase III ASCEND trial of Calquence(acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence monotherapy compared